A global health crisis is not the time to limit access to life-saving vaccines and medicines.

The federal government is considering new regulations that will put Canadians’ access to new vaccines and medicines at risk.

November 12, 2020 – A global health crisis is not the time to limit access to life-saving vaccines and medicines.

The federal government is considering new regulations that will put Canadians’ access to new vaccines and medicines at risk.

Sign your name, and share online, to help us stop these changes.

The height of an unprecedented global health crisis is not the time for federal government policy changes that will impact Canadians’ access to new and potentially life-saving vaccines and medicines.

This year alone, 39 new medications — for the treatment of cancer, Parkinson’s, and HIV, to name a few — have not been submitted to Health Canada for approval due to the uncertainty created by this proposed policy change.

This should not be happening in a country like Canada.

But it doesn’t have to be this way.

The federal government can delay their proposed changes and implement an alternative plan.

Industry has provided the federal government with an alternative plan that will ensure Canadians’ continue to have access to new vaccines and medicines, and that generate more than $20 billion in government savings and industry investments to help grow Canada’s life sciences sector, and provide programs to support those who need them most. The plan will also:

  • Provide mechanisms to ensure fair drug pricing;

  • Support the un-insured or under-insured by making product available to Canadians not eligible for, or whose public or private coverage is insufficient to provide the medicines they need;

  • Lead to a rare disease strategy that ensures Canadians get timely access to the lifesaving medicines they need; and

  • Include a commitment by industry to invest in a manufacturing or commercialization accelerator to help Canadian biotech entrepreneurs commercialize, scale, and locally manufacture.

Media enquiries